Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Kontafarma China Holdings Ltd ( (HK:1312) ).
Kontafarma China Holdings Ltd announced that its adjourned extraordinary general meeting successfully passed all proposed resolutions, including the approval of a significant construction contract for a research and development complex in Beijing. This contract, valued at over RMB33 million, is expected to enhance the company’s R&D capabilities, potentially strengthening its market position and benefiting stakeholders.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd is a company involved in the pharmaceutical industry, primarily focusing on research and development projects through its subsidiary, Tongfang Pharmaceutical.
Average Trading Volume: 5,871,050
Technical Sentiment Signal: Sell
Current Market Cap: HK$150.6M
Learn more about 1312 stock on TipRanks’ Stock Analysis page.